Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine
- 797 Downloads
Goals of the work
This study aimed to compare the effectiveness of mirtazapine and imipramine on not only the distressing symptoms of cancer patients such as pain, nausea, vomiting, appetite loss, and sleep disturbances but also depressive and anxiety symptoms.
Materials and methods
Fifty-three patients with cancer who were diagnosed with major depressive disorder, anxiety disorder, or adjustment disorder were included. Twenty patients on mirtazapine, 13 patients on imipramine, and 20 patients in the control group without medication were interviewed during three visits (baseline, third week, and sixth week). Pain, nausea, vomiting, appetite loss, and sleep disturbances were evaluated with self-assessment single-symptom scales during each visit. The patients were also asked to complete the Hospital Anxiety Depression Scale (HADS) during each visit.
There were no significant differences among the three visits in the mirtazapine, imipramine, or control groups in terms of pain, nausea, vomiting, or appetite loss. For the initial, middle, and late insomnia, only the mirtazapine group showed improvements (p = 0.001, p = 0.001, p = 0.003). There were also significant differences in the mean total (p = 0.03), anxiety (p = 0.003), and depression (p = 0.025) scores of HADS among the three visits for patients taking mirtazapine. There were no significant differences for HADS scores from the baseline to the end point for patients taking imipramine or control group patients.
Our findings suggest that mirtazapine is effective for resolving insomnia as well as anxiety and depressive symptoms in cancer patients. However, more systematic research, such as placebo-controlled studies, is needed.
KeywordsCancer Distressing symptoms of cancer Imipramine Mirtazapine
- 2.Akdemir A, Örsel S, Dağ I (1996) The reliability and validity of Hamilton Depression Rating Scale. The Journal of Psychiatry, Psychology and Psychopharmacology 4(4):251–259 (in Turkish)Google Scholar
- 4.Aydemir Ö, Güvenir T, Küey L, Kültür S (1997) The reliability and validity of Turkish form of hospital anxiety and depression scale. Journal of Turkish Psychiatry 8:280–287 (in Turkish)Google Scholar
- 5.Breitbart W, Payne DK (1998) Pain. In: Holland JC (ed) Psyco-oncology. Oxford University Press, New York, pp 450–468 (chapter 38)Google Scholar
- 8.Caraceni A, Cheville A, Portenoy RK (2000) Pain management: pharmacological and non-pharmacological treatments. In: Massie MJ (ed) Pain: what psychiatrists need to know. American Psychiatric Press Inc., Washington, DC, pp 23–69 (chapter 2)Google Scholar
- 12.First MB, Spitzer RL, Gibbon M (1997) Structured clinical interview for DSM-IV clinical version (SCID- I/CV). American Psychiatric Press, Washington, DCGoogle Scholar
- 13.Fleishman SB (1998) Cancer cachexia. In: Holland JC (ed) Psyco-oncology. Oxford University Press, New York, pp 468–476 (chapter 38)Google Scholar
- 22.Massie MJ, Popkin MK (1998) Depressive disorder. In: Holland JC (ed) Psyco-oncology. Oxford University Press, New York, pp 518–541 (chapter 45)Google Scholar
- 25.Ozkurkçugil A, Aydemir O, Yıldız M (1999) The reliability study of structured clinical interview for DSM-IV clinical version (SCID-I/CV). Journal of Drug and Treatment 12:233–236 (in Turkish)Google Scholar
- 33.Theobald DE (2000) A patient with B-cell lymphoma and major depression treated with mirtazapine. Primary Care & Depression and Anxiety 20(8):61–63 (September)Google Scholar
- 39.Williamss BW (1978) A structured interview guide for Hamilton Depression Rating Scale. Arch Gen Psychiatry 45:742–747Google Scholar